Cristina Magi-Galluzzi

Prof. Cristina Magi-Galluzzi

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
MFMihaela Farcaş
Mihaela Farcaş
ZGZoran Gatalica
Zoran Gatalica
Kiril TrpkovKiril Trpkov
Kiril Trpkov
JSJeffrey Swensen
Jeffrey Swensen
MZMing Zhou
Ming Zhou
Ondrej HesOndrej Hes
Ondrej Hes

1 February 2016 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
HDHari P. Dhakal
Hari P. Dhakal
JMJesse K. McKenney
Jesse K. McKenney
LKLi Yan Khor
Li Yan Khor
JRJordan P Reynolds
Jordan P Reynolds
CMCristina Magi-Galluzzi
Cristina Magi-Galluzzi
CPChristopher G. Przybycin
Christopher G. Przybycin
Clear cell papillary renal cell carcinoma (CCPRCC) was recently included in the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia as a subtype of RCC that is morphologically, immunohistochemically, and genetically distinct from both clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma. In our clinical practice we have observed tumors with overlapping histologic features of CCPRCC and CCRCC; therefore, our aim was to describe the morphologic, immunohistochemical, and clinical characteristics of these tumors. We examined a large series of consecutive nephrectomies diagnosed as CCRCC and found 37 tumors with morphologic overlap between CCRCC and CCPRCC, identifying 2 patterns. Pattern 1 tumors (N=19) had areas diagnosable as CCRCC admixed with foci having a prominent linear arrangement of nuclei away from the basement membrane imparting a resemblance to CCPRCC; however, other morphologic features commonly seen in CCPRCC (such as branching acini and cystic spaces with papillary tufts) were not typical and, when present, were focal or poorly developed. Pattern 2 (N=18) tumors had 2 discrete areas, one area with an appearance strongly resembling CCPRCC and the other with higher grade nuclei and features diagnosable as CCRCC, sometimes including rhabdoid differentiation, sarcomatoid differentiation, necrosis, and high-stage disease. Four (21%) of the pattern 1 tumors had grade 3 nuclei in the CCRCC-like areas, and 4 were high stage (pT3a). Of the 16 immunostained pattern 1 tumors, all expressed cytokeratin 7 (CK7) at least focally in the CCPRCC-like areas, strongly and diffusely in 9 (56%) cases; 12 (75%) showed negative to focal and/or weak CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, high–molecular-weight cytokeratin, and carbonic anhydrase IX (CA IX) had no significant differential expression between these foci. No cup-like staining pattern was seen with CA IX. Two (11%) patients with pattern 1 tumors developed metastases, and 1 (5%) subsequently died of disease. Eleven (61%) pattern 2 cases had the International Society of Urological Pathology grade 3 nuclei in the CCRCC-like areas, and 7 (39%) were grade 4 (4 of these cases had rhabdoid features; 1 was also sarcomatoid). Of the 16 immunostained pattern 2 tumors, 8 (50%) showed strong diffuse CK7 expression in the CCPRCC-like areas, and 9 (56%) showed complete lack of CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, and high-molecular-weight cytokeratin did not have significant differential expression. Membranous expression of CA IX, typically strong and diffuse, was identified in both the CCPRCC-like and CCRCC-like areas in all cases tested (with a cup-like pattern at least focally in the CCPRCC-like areas of 10 [63%] pattern 2 cases). Five (28%) patients with pattern 2 tumors had distant metastases, 3 (17%) of whom subsequently died of disease. Renal cell carcinomas with areas resembling both CCRCC and CCPRCC occur. Some can have high-grade and high-stage foci, and aggressive clinical outcomes are seen. Given this malignant potential, we would presently diagnose such cases as CCRCC. These 2 patterns of renal neoplasia underscore the need for caution in diagnosing CCPRCC on limited sampling, reserving the diagnosis for those tumors that strictly fulfill both morphologic and immunohistochemical criteria.

14 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
Andrea PalicelliAndrea Palicelli
Andrea Palicelli
Martina BonaciniMartina Bonacini
Martina Bonacini
Stefania CrociStefania Croci
Stefania Croci
CMCristina Magi-Galluzzi
Cristina Magi-Galluzzi
SCSofia Canete-Portillo
Sofia Canete-Portillo
MZMagda Zanelli
Magda Zanelli
Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines), which analyzes the immunohistochemical expression of PD-L1 in human PC samples and highlights the pre-analytical and interpretation variables. Interestingly, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ on immunohistochemistry. Different scoring methods or cut-off criteria were applied on variable specimen-types, evaluating tumors showing different clinic-pathologic features. The positivity rate of different PD-L1 antibody clones in tumor cells ranged from 3% (SP142) to 50% (ABM4E54), excluding the single case tested for RM-320. The most tested clone was E1L3N, followed by 22C3 (most used for pembrolizumab eligibility), SP263, SP142, and 28-8, which gave the positivity rates of 35%, 11–41% (depending on different scoring systems), 6%, 3%, and 15%, respectively. Other clones were tested in <200 cases. The PD-L1 positivity rate was usually higher in tumors than benign tissues. It was higher in non-tissue microarray specimens (41–50% vs. 15%), as PC cells frequently showed heterogenous or focal PD-L1-staining. PD-L1 was expressed by immune or stromal cells in 12% and 69% cases, respectively. Tumor heterogeneity, inter-institutional preanalytics, and inter-observer interpretation variability may account for result biases.

26 December 2022 in Human Pathology
Verified
Journal Article
Closed access
RMRahul Mannan
Rahul Mannan
XWXiaoming Wang
Xiaoming Wang
PBPushpinder S. Bawa
Pushpinder S. Bawa
SCSeema Chugh
Seema Chugh
ACAnya K. Chinnaiyan
Anya K. Chinnaiyan
RMRohit Mehra
Rohit Mehra

1 November 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
SHShuko Harada
Shuko Harada
ACAnna Caliò
Anna Caliò
KJKaren M. Janowski
Karen M. Janowski
DMDiana Morlote
Diana Morlote
MPMaria D. Rodriguez Pena
Maria D. Rodriguez Pena
AMAlexander Craig Mackinnon
Alexander Craig Mackinnon

1 April 2020 in Human Pathology
Verified
Journal Article
Closed access
JNJane K. Nguyen
Jane K. Nguyen
CPChristopher G. Przybycin
Christopher G. Przybycin
JMJesse K. McKenney
Jesse K. McKenney
CMCristina Magi-Galluzzi
Cristina Magi-Galluzzi